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Background: In COPD, although histological lesions at both the small airways (wall thickening and
tissue remodeling) and lung parenchyma (emphysematous destruction) are definitely different,
the inflammatory cells involved in both processes are the same. Our study aims to determine if
these histopathological phenotypes are related to two different lymphocyte profiles.
Methods: Distribution and cell density of CD3þ, CD4þ, CD8þ and B lymphocytes were compared in
small airways and parenchymal interstitium of 9 non-smokers, 18 smokers without COPD, 16
smokerswithmoderate COPD and 16 patients with very severe COPD undergoing lung transplanta-
tion. Spatial distribution of lymphocytes in periemphysematous parenchyma was also assessed.
Results: CD3þ and B cell densities were significantly higher in small airways than parenchyma in-
terstitiumofvery severeCOPDpatients. Furthermore,CD8þ cellswere increased in theepithelium
of airways of moderate COPD patients compared to non-smokers. Although CD8þ cell density was
increased inparenchymaofCOPDpatients, CD8þ andBcell densitieswere similarwhencomparing
periemphysematous and non-emphysematous alveolar interstitium.
Conclusions: In COPD, it is true that the small airways’ wall shows a clear inflammatory pattern,
with a high mononuclear infiltration and tissue remodeling. However, parenchymal interstitium
shows a milder CD8þ infiltration which, moreover, is not spatially related to emphysematous de-
stroyed areas.
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Differential lymphocyte infiltration in COPD 1311Introduction MethodsChronic obstructive pulmonary disease (COPD) is defined as
an abnormal inflammatory response of the lung to noxious
particles and gases, mainly cigarette smoke.1
The main pathological features of COPD are found in
small airways and lung parenchyma, although the histo-
logical alterations in these two compartments are
different. Thus, COPD is associated with tissue remodeling
(fibrosis and smooth muscle hypertrophy) in small airways;
while in lung parenchyma tissue destruction predominates,
leading to emphysema.2,3 Recent studies show that
lymphocytes may play a key role in enhancing and main-
taining the inflammatory response in the aforementioned
compartments affected in COPD.4
Some information has been published on lymphocyte
infiltration in small airways of COPD patients.5e10 Unlike
with asthma, CD4þ cells do not seem to be involved in COPD
pathogenesis, since the number of both total T cells5,6 and
helper T cells6,7 was similar in the small airways of smokers
with and without COPD. However, a higher number of CD8þ
cells7,8 and B-cells9 has been detected in the wall of small
airways of smokers with COPD compared with smokers
without COPD. Furthermore, an inverse correlation
between the bronchiolar infiltration of these cells and FEV1
was detected in a cohort of COPD patients in different
GOLD stages.10
Few data are available about the extent of lymphocyte
infiltration in parenchyma, especially in the most severe
forms of COPD. Two studies reported that COPD patients
have an increased number of CD8þ cells in alveolar wall
compared with control non-smokers.11,12 Another one
showed a relationship between the increase of CD4þ and
CD8þ cells and the severity of the disease, without differ-
ences in B lymphocytes.13
In spite of this evidence, as far as we know, no studies
have been carried out analyzing lymphocyte infiltration in
the two compartments affected in COPD; i.e., small
airways and lung parenchyma. Likewise, although the
number of lymphocytes infiltrating lung parenchyma
correlates with the degree of microscopic emphy-
sema,14,15 the localization and distribution of lympho-
cytes in the areas nearest to emphysema remain
unexplored.
Given that in COPD small airways and lung parenchyma
are infiltrated by the same inflammatory cells (T and B
lymphocytes and macrophages), a research question
remains to be elucidated: Are there differences in type
and/or cell density of infiltrating lymphocytes between the
two compartments? Additionally, assuming that CD8þ
lymphocytes have been correlated with parenchymal
destruction, a second research question emerges: Is there
a spatial association of these cells with emphysematous
lesions?
In order to shed light on these questions, our study
carries out a systematic exploration of the lymphocyte
subsets in bronchiolar compartments (epithelium, smooth
muscle and connective tissue) and alveolar interstitium in
samples from smokers with moderate and very severe
COPD and in subjects without COPD (smokers and non-
smokers).Subjects
The study population comprised 59 subjects who underwent
lung resection for non-obstructive peripheral lung tumors or
were subjected to double lung transplantation for very
severe COPD. The study was approved by the Ethics
Committee of the Vall d’Hebron Hospital (Barcelona, Spain)
and a written informed consent was obtained from all
patients. Spirometry and diffusing capacity measurements
and body plethysmography were performed to assess
pulmonary function using standard procedures16 and
equipment (Masterlab; Jaeger, Wu¨rzburg, Germany). None
of the subjects had had a COPD exacerbation nor had
received chemotherapy before surgery.
Patients were classified into 4 clinical groups according
to their smoking habits (smokers and non-smokers) and
COPD severity1: 9 nonsmoking patients with normal lung
function; 18 asymptomatic smokers with normal lung
function; 16 smokers with moderate COPD (GOLD stage II);
and 16 smokers with very severe COPD (GOLD stage IV)
subjected to double lung transplantation.
Sample processing
Immediately after surgery, the excised lungs or lobes were
inflated by intrabronchial injection of 4% formaldehyde at
a constant pressure prior to immersion in fixative during
24 h. After fixation, surgical specimens were sliced and the
severity of emphysema (macroscopic emphysema degree,
MED, %) was graded using a panel grid as previously
described.17 This parameter shows a statistically significant
correlation with HRCT, reflecting the extent of paren-
chymal damage.18,19 After that, 2 2 0.3 cm randomly
selected tissue blocks were excised, embedded in paraffin,
cut into 4-mm sections and mounted on positive charged
slides Starfrost Plus (Menzel-Gla¨ser, Braunschweig,
Germany).
Immunohistochemistry
The following antibodies were used at indicated dilutions:
polyclonal anti-CD3 (1:400; DakoCytomation, Glostrup,
Denmark), monoclonal anti-CD4 (1:50; Novocastra, New-
castle, UK), monoclonal anti-CD8 antigen (1:100; DakoCy-
tomation) and monoclonal anti-CD20cy (1:800;
DakoCytomation). Immunostaining was performed using the
ABC immunoperoxidase method (Vectastain Elite ABC kit;
Vector Laboratories, Burlingame, CA) with a DAB reaction.
Cell counts
Cell density for each marker and sample was assessed using
a point-counting method previously described.20,21 Briefly,
at least twelve fields were randomly and systematically
sampled to assess cell densities in alveolar interstitium
and bronchiolar wall by using a grid with a known area
attached to the eye piece of the microscope. The number
of points hitting parenchymal interstitium and bronchiolar
1312 J. Olloquequi et al.epithelium, connective tissue and smooth muscle were
counted and converted into square millimeters using
a conversion factor calculated for the specific magnifica-
tion. In each field, the number of cells was determined by
counting the cell profiles that were not in vessels or inter-
sected by the exclusion lines.
To assess the spatial association of lymphocytes with
destroyed parenchyma, we measured CD8þ and B cells in
alveolar interstitium of three fields in proximal peri-
emphysematous parenchyma (100 to 300 mm away from
emphysema), and three more fields in distal peri-
emphysematous parenchyma (300 to 600 mm away from
emphysema), in patients with COPD.
Cell densities were expressed as number of cells per
square millimetres of tissue examined.5,7,8,13,22,23 Mean
patient values were obtained by averaging the results of all
fields. The cases were coded and the measurements made
without knowledge of clinical data.
Blood analysis
Blood samples were taken from all patients immediately
before surgery. Total cell counts and lymphocyte subsets
were determined as previously described.24
Statistical analysis
Descriptive statistical analysis included means and stan-
dard errors for each parameter. Differences among groups
were analyzed using the analysis of variance (ANOVA) for
clinical data and the KruskaleWallis test for cell densities.
When differences in cell densities were significant, the
KruskaleWallis test was followed by the ManneWhitney U
test for comparison between groups. Correlations were
calculated by Spearman’s rank correlation test.Table 1 Clinical and demographical data.
Non-smokers
(nZ 9)
Sm
CO
Sex, Male/Female 1/8 14
Age, years 61.78 4.62 60
Smokig history, pack-years 0.00 0.00 49
Smoking status, current/ex-smoker e 8/
Inhaled corticosteroids
use, yes/no
1/8 1/
Exacerbations in the previous year e e
FEV1, % predicted 99.34 8.16 84
FEV1/FVC, % predicted 80.07 2.77 78
RV, % predicted 107.53 10.17 98
TLC, % predicted 101.02 2.82 90
DLCO, % predicted 82.13 7.86 71
MED, % predicted 1.67 1.10 13
Definition of abbreviations: FEV1: forced expiratory volume in 1 secon
capacity; DLCO: carbon monoxide diffusing capacity; MED: macroscop
Values expressed as mean SEM.
a Different from control non-smokers (p< 0.001).
b Different from smokers without COPD (p< 0.001).
c Different from moderate COPD patients (p< 0.001).Significance level was set at p< 0.05. All analyses were
performed using Statgraphics Centurion XV (StatPoint Inc.,
Virginia, USA).
Results
Demographic and clinical findings
Patient characteristics are presented in Table 1. The four
groups of patients were similar with regard to age, and
there was no significant difference in pack-years between
smokers with and without COPD. As expected from the
selection criteria, non-smokers and smokers without COPD
had normal lung function, whereas patients with COPD
showed significant alterations in spirometry parameters,
such as FEV1, FEV1/FVC and DLCO. In addition, there was
a significantly increased MED in COPD patients compared to
subjects without COPD (Table 1).Immunohistochemistry
Small airways
In order to determine whether the inflammatory response
was different in epithelium, connective (subepithelial and
adventitial) or smooth muscle tissues of small airways, we
assessed the lymphocyte density for each one of these
histological compartments for all patients.
Regarding T lymphocytes, only the number of CD8þ cells
revealed some differences when the four groups were
compared. Indeed, COPD patients showed more CD8þ
lymphocytes in small airways than subjects without COPD,
and a significantly higher density of these cells was found in
the epithelial layer of subjects with moderate COPD in
comparison to control non-smokers (Figs. 1 and 2A and B).okers without
PD (nZ 18)
Moderate COPD
(nZ 16)
Very severe COPD
(nZ 16)
/4 16/0 13/3
.94 2.58 63.34 2.01 55.93 1.34
.89 5.86 61.44 5.35 47.87 5.72
10 14/2 0/16
17 7/9 14/2
0.6 0.7 2.0 1.3
.98 2.57 69.34 4.52a,b 20.78 1.22a,b,c
.99 1.86 61.78 4.64a,b 35.18 2.01a,b,c
.08 7.69 146.06 7.82 282.65 23.02a,b,c
.5 3.75 113.76 3.70 135.17 9.00a,b,c
.62 4.21 57.56 3.03a,b 34.79 4.01a,b,c
.89 3.81 59.14 1.99a,b 67.50 4.03a,b,c
d; FVC: forced vital capacity; RV: residual volume; TLC: total lung
ic emphysema degree.
Figure 1 Lymphocyte infiltration in bronchiolar compart-
ments. (A) Lymphocyte density in the epithelial layer. Despite
the differences observed in the estimation of cell densities in
bronchiolar epithelium, only that found between moderate
COPD patients and non-smokers became significant. (B)
Lymphocyte density in the connective compartment. Very
severe COPD patients showed a significantly higher density of B
cells in bronchiolar connective tissue when compared with the
rest of groups. *Different from control non-smokers (p< 0.05).
y Different from smokers without COPD (p< 0.05). z Different
from moderate COPD patients (p< 0.05).
Differential lymphocyte infiltration in COPD 1313Moreover, patients with moderate COPD also showed
a significantly higher density of CD8þ cells in total small
airway tissue than non-smokers (Figs. 2A and B and 3A). The
infiltration in smooth muscle was minimal and no statistical
differences were observed among the four groups (data not
shown).
The comparison of CD4þ/CD8þ ratio in epithelium
allowed us to differentiate the groups when smoking
condition was considered. Thus, we observed that the ratio
of CD4þ/CD8þ cells was lower than 1.0 in the epithelium of
smokers, whereas non-smokers showed a CD4þ/CD8þ ratio
higher than 1.0 (pZ 0.02, Table 2).
Finally, the number of B-lymphocytes in the connective
tissue of small airways of subjects with very severe COPDwassignificantly higher than in the other groups (Figs. 1B and 2C,
D). However, no differences were found in the density of
these cells in epithelium or in smooth muscle, nor in the
small airway’s wall, among the four clinical groups.
Lung parenchyma
As was found in small airways, the density of CD8þ cells in
interstitium was significantly higher in patients with COPD
compared to patients without COPD (Figs. 3A and 4A and B).
Importantly, when CD8þ cell density was compared
between the interstitium closer to emphysematous areas
(proximal parenchyma) and the interstitium located farther
than 300 mm from the border of emphysematous destruc-
tion (distal parenchyma) in COPD patients, no significant
differences were observed (Table 3 and Fig. 4C).
Regarding B-lymphocyte densities, patients with very
severe COPD had the highest number of these cells
(25.17 8.67 cell/mm2), although the difference from the
other groups was not significant (Fig. 3D). Furthermore,
there were no significant differences in B cell numbers
between proximal and distal periemphysematous paren-
chyma in COPD patients (Table 3).
Small airways versus lung parenchyma
When the extent of lymphocytes infiltrating small airways
and lung parenchyma interstitium was compared, we
observed that COPD patients presented a higher CD3þ
density in the bronchiolar tissue. Patients with moderate
and very severe COPD showed a significantly higher number
of CD3þ cells in bronchiolar wall (433.38 70.73 cell/mm2
and 359.77 89.41 cell/mm2, respectively) than in paren-
chymal interstitium (235.67 47.87 cell/mm2 and
166.67 32.08 cell/mm2, respectively) (p 0.03, Fig. 3C).
Moreover, very severe COPD patients had a significantly
increased density of B cells in bronchiolar tissue
(99.82 22.07 cell/mm2) compared to parenchyma
(25.17 22.07 cell/mm2, p 0.01, Fig. 3D). By contrast, no
significant differences were found between bronchiolar and
parenchymal densities of CD3þ and B cells in non-smokers
and smokers without COPD (Fig. 3C and D).
Additionally,weobserved ahigher infiltrationofCD4þ cells
in small airways than in parenchyma of all groups (Fig. 3B).
Moreover, smokers without COPD and moderate COPD
patients also showed a significant increase of CD8þ in bron-
chiolar wall compared to parenchymal interstitium (Fig. 3A).
Correlations
Some correlations were found between lymphocyte densi-
ties and clinical data when all smokers were considered
together. The number of pack-years smoked was positively
correlated with the cell density of CD8þ lymphocytes
infiltrating the total small airway (RZ 0.28, pZ 0.04),
bronchiolar connective compartment (RZ 0.32, pZ 0.02)
and epithelium (RZ 0.30, pZ 0.03). Moreover, a signifi-
cant correlation was also found between the number of
CD8þ cells in alveolar interstitium and pack-years
(RZ 0.27, pZ 0.03), as well as RV (RZ 0.35, pZ 0.02)
values. On the contrary, there were no significant correla-
tions between the macroscopic emphysema degree and the
density of CD8þ in small airway or parenchymal inter-
stitium. Regarding B-lymphocytes, there was an inverse
correlation between the density of these cells in the total
Figure 2 Immunolocalization of lymphocyte subpopulations in small airways. (A, B) CD8þ T lymphocytes infiltrating small airways
of a control nonsmoker (A) and a patient with moderate COPD (B). BarsZ 75 mm (A) and 100 mm (B). (C, D) Infiltration of B
lymphocytes in a small airway of a smoker without COPD (C) and a patient with very severe COPD (D). BarsZ 100 mm.
Figure 3 Lymphocyte densities in bronchiole wall and lung parenchyma. (A) CD8þ lymphocytes, (B) CD4þ lymphocytes, (C) CD3þ
lymphocytes, (D) B lymphocytes. *Different from control non-smokers (p< 0.05). y Different from smokers without COPD (p< 0.05).
Different from parenchyma (p< 0.05).
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Table 2 CD4þ/CD8þ ratio in bronchiolar compartments.
Non-smokers
(nZ 9)
Smokers without COPD
(nZ 18)
Moderate COPD
(nZ 16)
Very severe COPD
(nZ 16)
Epithelium 3.14 1.75 0.40 0.10a 0.61 0.25a 0.47 0.23a
Connective tissue 1.57 0.47 1.05 0.22 0.42 0.12 0.58 0.13
Smooth muscle 1.07 0.20 0.51 0.14 1.04 0.36 0.42 0.14
Values expressed as mean SEM.
a Different from control non-smokers (pZ 0.02).
Differential lymphocyte infiltration in COPD 1315small airway, as well as in the connective compartment,
and the FEV1 values (RZ0.37, pZ 0.02 and RZ0.39,
pZ 0.01, respectively).
When control smokers were excluded from the analysis,
only the correlation between the density of B-cells in the
bronchiolar compartment and the FEV1 values was main-
tained (RZ0.54, pZ 0.008). No other correlations were
found between lymphocyte densities and clinical parame-
ters, including DLCO and MED.
Blood lymphocytes
The estimation of the number of each lymphocyte subset
per mL of blood showed no significant differences among
the four clinical groups (data not shown). Moreover, no
correlations have been found between lymphocyte
numbers in blood and those infiltrated into the tissue
compartments.
Discussion
Two histopathological phenotypes have been described in
COPD: remodeling in small airways and emphysema in
parenchyma. There is emerging evidence that lymphocyte-
mediated inflammation in both compartments may
contribute to progression of COPD.25 The present study
demonstrates that T and B lymphocyte infiltration is signifi-
cantly higher in small airways than in parenchymal inter-
stitium of very severe COPD patients. Moreover, no spatial
relationship was found between lymphocyte infiltration and
emphysematous areas in the examined samples from COPD.
Regarding the CD8þ lymphocyte subset, our results
suggest that, while cigarette smoke increases CD8þ cell
density in small airways of all smokers, there is a significant
and specific increase of these cells in the parenchymal
interstitium of COPD patients. Furthermore, we found that
CD8þ cell density was always higher in small airways than in
lung parenchyma of COPD patients, although significant
differences were found only in the moderate COPD group.
This is not surprising, as very severe COPD patients had
a lower density of CD8þ cells in airways than moderate
COPD patients, while density in lung parenchyma was
similarly increased in both COPD groups. Although some
studies report an increase of CD8þ cells in small airways
with the severity of the disease,8,10 previous findings of Di
Stefano and colleagues22 showed that subjects at severe
stages of COPD have a lower number of CD8þ lymphocytes
in bronchial mucosa than mild/moderate COPD patientsand control smokers. A possible explanation is that all
patients with very severe COPD had stopped smoking some
years before, and smoking cessation has been associated
with a decrease of CD8þ cell numbers in the airways.26
Another explanation may be the higher number of
patients treated with inhaled corticosteroids in the group
of very severe COPD (14/16), since these steroids drasti-
cally lower CD8þ cells in the airways.27
The assessment of each bronchiolar compartment
allowed us to detect whether lymphocyte infiltration was
more severe in epithelium, smooth muscle or connective
tissue. Importantly, we have demonstrated that moderate
COPD patients have a higher density of CD8þ cells in the
epithelium of small airways than non-smokers. This finding
adds further information to previous observations of Four-
nier and coworkers,28 who reported an increase of intra-
epithelial CD8þ lymphocytes in central airways of subjects
with chronic bronchitis and airflow limitation. Furthermore,
smokers with and without COPD showed a predominance of
the CD8þ over the CD4þ T cell phenotype (CD4þ/CD8þ< 1)
in the epithelial layer compared with non-smokers;
whereas, in the connective tissue, the ratio CD4þ/CD8þ
was reversed only in COPD patients. Additionally, when we
considered all smokers as one group, a positive correlation
was found between the CD8þ cell density in small airways
and the pack-years smoked, adding new data to previous
findings concerning large airways.29 Taken together, these
results suggest that cigarette smoke induces a modification
of the lymphocyte profile in the epithelium of small airways
by increasing the number of CD8þ cells.
With respect to lung parenchyma, as far as we know, our
study is the first to provide data about the number of
lymphocytes in patients who underwent double lung
transplantation for very severe COPD. We have found an
increased density of CD8þ cells in the alveolar interstitium,
which was specific to COPD patients; however, the CD8þ
increase in airways was also observed in smokers without
COPD. This finding is in line with previous studies reporting
higher numbers of CD8þ lymphocytes in lung parenchyma of
subjects with moderate or severe COPD.11e13 Moreover,
similar to the finding concerning small airways, the number
of CD8þ cells in parenchymal interstitium was positively
correlated with the number of packs-year smoked, as
previously described by Majo´ and colleagues.12
However, when the localization of lymphocytes in the
emphysematous lung parenchyma was analyzed, we
observed that the number of CD8þ and B cells in the
interstitium adjacent to the border of emphysematous
areas was similar to that found in non-affected
Figure 4 Immunolocalization of lymphocyte subpopulations
in lung parenchyma. (A, B) Infiltration of CD8þ T lymphocytes
in a parenchyma of a smoker without COPD (A) and a patient
with very severe COPD (B). (C) Periemphysematous lung
parenchyma immunostained for CD8þ T lymphocytes. Alveolar
walls of periemphysematous parenchyma did not achieve
a higher infiltration of CD8þ cells than those of non-affected
parenchyma. BarsZ 125 mm.
Table 3 Lymphocyte densities in periemphysematous
parenchyma.
Distal
parenchyma
Proximal
parenchyma
CD8þ, cells/mm2 95.66 18.58 87.79 16.81
CD20þ, cells/mm2 4.97 2.50 6.76 3.90
Values expressed as mean SEM.
No significant differences were found.
1316 J. Olloquequi et al.parenchyma. So, in spite of the higher density of CD8þ
lymphocytes in COPD patients, the distribution of these
cells was uniform throughout the parenchyma and no
accumulations were found in proximal-emphysematous
regions. Since the effector functions of these lymphocytesoccur after recognition of and adhesion to target cells,30
and lymphocyte proximity to affected area is necessary to
induce cell apoptosis, these results do not support the
hypothesis linking CD8þ cells with development of emphy-
sema. Furthermore, no correlation was found between the
parenchymal density of CD8þ or B cells and the macroscopic
emphysema degree or the FEV1 values.
We believe our data rather support the previously
formulated speculation that the increase of CD8þ and, to
a lesser extent, B cells in lung parenchyma of COPD patients
might be a consequence of emphysema. As previously sug-
gested,8,10,11,13,31 it is likely that repeated viral or bacterial
infections, known to be frequent in COPD patients, could
account for the increased lymphocyte numbers in the lungs
of these subjects. Moreover, Hogan and colleagues32
demonstrated in a murine model that antigen-specific
CD8þ cells can persist in lung tissue and airways for several
months after clearance of a respiratory virus. Nonetheless,
we are aware that emphysema is a long-term process and
further studies are necessary to understand whether CD8þ
lymphocytes have a direct role in its progression.
Finally, the comparison between bronchiolar and
parenchymal compartments showed that all lymphocyte
densities were higher in bronchiolar wall than in alveolar
interstitium, regardless of cell type and the group consid-
ered. Statistically, the difference was significant in CD3þ
and B lymphocytes in very severe COPD patients. Histo-
pathological patterns in small airways and lung parenchyma
are different in COPD, with both alterations coexisting in
most patients. Since lymphocyte types are the same, their
contribution to the different histopathological patterns in
both compartments is difficult to understand with available
data. However, although the structure of alveolar inter-
stitium and small airways is different, there is no evidence
that lymphocyte function varies depending on the infil-
trated tissue. Consequently, the simplest explanation for
these results is probably that lymphocytes take part in
different processes leading to chronic airflow obstruction.
We think that a plausible hypothesis is that, while the
lymphocytes are involved in a high inflammatory response
to smoking in the small airways, with a great number of
infiltrating cells producing fibrosis and smooth muscle
hypertrophy, in lung parenchyma, lymphocytes are the
result, but not the cause, of a mild inflammation with
a lower number of infiltrating cells resulting from the
emphysematous areas.
In summary, our results show that responses in small
airways and lung parenchyma to cigarette smoke in COPD
patients are different in terms of lymphocyte infiltration.
Both CD8þ and B cells are the main lymphocyte subsets
Differential lymphocyte infiltration in COPD 1317involved in the pathogenesis of small airways in COPD,
where these cells could play a role in tissue remodeling
and airway obstruction. By contrast, although COPD
patients showed an increased density of CD8þ cells in lung
parenchyma, the fact that these cells were not prefer-
entially infiltrated into the alveolar walls adjacent to
emphysematous destruction, even in patients at the most
severe stage of COPD, challenges the hypothesis attrib-
uting emphysema to CD8þ lymphocytes. Further investi-
gation on the role of other cells, such as neutrophils,33 and
processes, such as oxidative stress, could provide impor-
tant data in order to elucidate the pathogenesis of the
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